{"id":46485,"date":"2022-07-22T16:02:05","date_gmt":"2022-07-22T14:02:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/applied-dna-biotherapeutics-subsidiary-linearx-to-present-data-showcasing-advantages-of-its-enzymatically-produced-lineardna-as-substitute-for-plasmid-dna-in-ivt-mrna-production-at-the-2nd-annual-mrna\/"},"modified":"2022-07-22T16:02:05","modified_gmt":"2022-07-22T14:02:05","slug":"applied-dna-biotherapeutics-subsidiary-linearx-to-present-data-showcasing-advantages-of-its-enzymatically-produced-lineardna-as-substitute-for-plasmid-dna-in-ivt-mrna-production-at-the-2nd-annual-mrna","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/applied-dna-biotherapeutics-subsidiary-linearx-to-present-data-showcasing-advantages-of-its-enzymatically-produced-lineardna-as-substitute-for-plasmid-dna-in-ivt-mrna-production-at-the-2nd-annual-mrna\/","title":{"rendered":"Applied DNA Biotherapeutics Subsidiary LineaRx to Present Data Showcasing Advantages of its Enzymatically Produced LinearDNA as Substitute for Plasmid DNA in IVT mRNA Production at the 2nd Annual mRNA-Based Therapeutics Summit"},"content":{"rendered":"
\n

\n– Industry Leaders Will Learn How LinearDNA Can Significantly Improve RNA Manufacturing Speed, Simplicity, and Scalability in Comparison to Plasmid DNA –<\/i>\n<\/p>\n

STONY BROOK, N.Y.–(BUSINESS WIRE)–$APDN<\/a> #LinearDNA<\/a>—Applied DNA Sciences, Inc.<\/a> (NASDAQ: APDN) (the \u201cCompany\u201d), a leader in PCR-based technologies, today announced that Dr. James A. Hayward, president and CEO of Applied DNA and its majority-owned biotherapeutics subsidiary, LineaRx Inc., will present data highlighting the advantages of its enzymatically produced linearDNA (linDNA) as an IVT template for mRNA production at the 2nd<\/sup> Annual mRNA-Based Therapeutics Summit<\/a> on July 26-28, 2022, in Boston, Massachusetts.\n<\/p>\n

<\/a><\/p>\n

\nDr. Hayward\u2019s presentation, titled \u2018The Future of RNA Therapies Produced from LinearDNA\u2122 Templates,\u2019 is scheduled for Wednesday, July 27, at 4:30pm EST at Hilton Boston Logan Airport. A copy of the slide presentation will be made available to interested parties concurrent with the start of the presentation at https:\/\/linearxdna.com\/<\/a>.\n<\/p>\n

\nLineaRx staff will be available at Booth 3 at the Summit. To schedule a meeting, contact: brian.viscount@adnas.com<\/a>.\n<\/p>\n

\nlinDNA is an optimal IVT template for mRNA production as compared to plasmid DNA (pDNA). Produced by the LinearDNA\u2122 platform, a cell-free enzymatic manufacturing platform for the large-scale production of high-fidelity DNA sequences for use in nucleic acid-based therapeutics, linDNA enables:\n<\/p>\n